NCT05838287View on ClinicalTrials.gov

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

PHASE4RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

August 31, 2029

Study Completion Date

January 31, 2030

Conditions
Type 2 Diabetes Mellitus in ObeseHeart Failure With Preserved Ejection Fraction
Interventions
DRUG

Pioglitazone

Participants will be taking Pioglitazone tablets 1/day for 24 weeks.

DRUG

Placebo

Placebo for Pioglitazone

Trial Locations (1)

78229-3900

RECRUITING

Texas Diabetes Institute/UH, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER